Skip to main content
This website uses cookies to ensure you get the best experience. By continuing to use this site, you agree to the use of cookies.

Please note: Your browser does not support the features used on Addgene's website. You may not be able to create an account or request plasmids through this website until you upgrade your browser. Learn more

Please note: Your browser does not fully support some of the features used on Addgene's website. If you run into any problems registering, depositing, or ordering please contact us at [email protected]. Learn more

p-AAV-sh[SNCA] Citations (2)

Originally described in: shRNA targeting alpha-synuclein prevents neurodegeneration in a Parkinson's disease model.
Zharikov AD, Cannon JR, Tapias V, Bai Q, Horowitz MP, Shah V, El Ayadi A, Hastings TG, Greenamyre JT, Burton EA J Clin Invest. 2015 Jul 1;125(7):2721-35. doi: 10.1172/JCI64502. Epub 2015 Jun 15.
PubMed Journal

Articles Citing p-AAV-sh[SNCA]

Long-term RNAi knockdown of alpha-synuclein in the adult rat substantia nigra without neurodegeneration. Zharikov A, Bai Q, De Miranda BR, Van Laar A, Greenamyre JT, Burton EA. Neurobiol Dis. 2019 May;125:146-153. doi: 10.1016/j.nbd.2019.01.004. Epub 2019 Jan 15. PubMed
alpha-Synuclein amplifies cytoplasmic peroxide flux and oxidative stress provoked by mitochondrial inhibitors in CNS dopaminergic neurons in vivo. Van Laar VS, Chen J, Zharikov AD, Bai Q, Di Maio R, Dukes AA, Hastings TG, Watkins SC, Greenamyre JT, St Croix CM, Burton EA. Redox Biol. 2020 Oct;37:101695. doi: 10.1016/j.redox.2020.101695. Epub 2020 Aug 22. PubMed

If you have published an article using this material, please email us at [email protected] to have your article added to this page.